SUPPORTIVE CARE
All our patients were treated in protective private HEPA (high-efficiency-particulate-air) filtered positive pressure rooms. Infectious prophylaxis (antimicrobial, antiviral and antifungal) was administered as per our institutional guidelines. All patients received weekly monitoring of qualitative/quantitative polymerase chain reaction (PCR) for Epstein Barr virus (EBV), Adenovirus, CMV and Human herpes virus-6 (HHV-6). Treatment was guided by quantitative viral loads when positive. Since May 2020, all patients are required to have a COVID19 (Coronavirus disease 2019) nasopharyngeal PCR swab prior to admission, procedures or at the emergence of new symptoms suggestive of an infection. Acute GVHD was graded according to modified Glucksberg criteria and chronic GVHD was scored based on National Institutes of Health global severity criteria (18, 19). Chimerism studies were performed at the time of WBC recovery.